Summary
In this study we performed a detailed imaging characterization (workflow below) of this model, details are provided in the attached standard operating procedures. Tumors in half of the mice were resected in the range 200-300 mm3 size; tumors in the other half were allowed to grow until it was necessary to euthanize them because of tumor size.
T2w MRI at 56 days post implant demonstrated a heterogenous tumor with an apparent central hemorrhage and the implant appears to have a defined capsule. On day 98 (post-implant) the tumor increased in size (618%) with very similar imaging characteristics as displayed on day 56.
In contrast, the regrowth following surgical resection of the primary xenograft (105 days post resection) is homogenous, but also appears to have a well-defined capsule.
PET/CT Characterization of the primary tumor: Baseline PET (SOP attached) were performed when tumor reached an approximate 200 mm3. Average SUVbw_max values (n=5) were calculated; [18F]FDG: 1.8 ± 0.2 and [18F]FLT: 2.8 ± 0.7.
The imaging characteristics of this model, which is available from the National Cancer Institute Patient-Derived Models Repository (https://pdmr.cancer.gov/), is highly favorable for preclinical research studies when used in conjunction with non-contrast T2 weighted MRI.
Acknowledgements
Frederick National Laboratory for Cancer Research – Special Thanks to Joseph D. Kalen, PhD, Lilia V. Ileva, MS, Lisa A Riffle, Nimit Patel, Keita Saito, PhD, Yvonne Evrard, PhD, Jessica Phillips, Simone Difilippantonio, PhD, Chelsea Sanders, Amy James, Lia Thang, Ulrike Wagner, Yanling Liu, PhD, John B. Freymann, and Justin Kirby.
Division of Cancer Therapeutics and Diagnosis/National Cancer Institute - James L. Tatum, MD, Paula M Jacobs, PhD, Melinda G. Hollingshead, DVM, and James H. Doroshow, MD
PixelMed Publishing – Special Thanks to David A. Clunie, MD
University of Arkansas for Medical Sciences – Special Thanks to Kirk E. Smith
This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract Number HHSN261201500003I. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
Data Access
Data Type | Download all or Query/Filter | License |
---|---|---|
Images (DICOM, 1.6 GB) |
(Download requires NBIA Data Retriever) | |
Standard Operating Procedure 50101: MRI T2 Weighted Non-Contrast Protocol: Single Mouse Pulmonary Gated and Multi-Mouse Non-Gated (pdf, 141 kB) | ||
Standard Operating Procedure 50102: Positron Emission Tomography PET imaging protocol (pdf, 150 kB) |
Additional Resources for this Dataset
The National Cancer Institute (NCI) has developed a national repository of Patient-Derived Models (PDMs) comprised of patient-derived xenografts (PDXs), in vitro patient-derived tumor cell cultures (PDCs) and cancer associated fibroblasts (CAFs) as well as patient-derived organoids (PDOrg). These models serve as a resource for public-private partnerships and for academic drug discovery efforts. These PDMs are clinically-annotated with molecular information and made available in the Patient-Derived Model Repository. Data related to the specific subjects in this Collection can be found at:
Click the Versions tab for more info about data releases.
Detailed Description
Image Statistics | |
---|---|
Modalities | MR, SR |
Number of Subjects | 20 |
Number of Studies | 100 |
Number of Series | 180 |
Number of Images | 2980 |
Images Size (GB) | 1.8 GB |
In addition to images, this collection includes Raw Data Storage SOP Class instances with MR Modality, generated by a Philips MR scanner; this data is not useful to anyone without the proprietary software to interpret it.
Citations & Data Usage Policy
Users must abide by the TCIA Data Usage Policy and Restrictions. Attribution should include references to the following citations:
Data Citation
Tatum, J., Kalen, J., Ileva, lilia, Riffle, L., Keita, S., Patel, N., Jacobs, P., Sanders, C., James, A., Difilippantonio, S., Thang, L., hollingshead, melinda, Phillips, J., Evrard, Y., Clunie, D., Yanling, Smith, K., Wagner, U., Freymann, J., … Doroshow, J. (2020). Imaging tissue characterization of a patient derived xenograft model of adenocarcinoma pancreas: (PDMR-833975-119-R) [Data set]. The Cancer Imaging Archive. https://doi.org/10.7937/TCIA.0ECK-C338
TCIA Citation
Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P, Moore S, Phillips S, Maffitt D, Pringle M, Tarbox L, Prior F. The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository, Journal of Digital Imaging, Volume 26, Number 6, December, 2013, pp 1045-1057. DOI: 10.1007/s10278-013-9622-7
Other Publications Using This Data
TCIA maintains a list of publications which leverage TCIA data. If you have a manuscript you'd like to add please contact the TCIA Helpdesk.
Version 1 (Current): Updated 2020/10/05
Data Type | Download all or Query/Filter |
---|---|
Images (DICOM, 1.7 GB) | (Download requires the NBIA Data Retriever) |
SOP50101: MRI T2 Weighted Non-Contrast Protocol: Single Mouse Pulmonary Gated and Multi-Mouse Non-Gated |
Additional Resources for this Dataset
The National Cancer Institute (NCI) has developed a national repository of Patient-Derived Models (PDMs) comprised of patient-derived xenografts (PDXs), in vitro patient-derived tumor cell cultures (PDCs) and cancer associated fibroblasts (CAFs) as well as patient-derived organoids (PDOrg). These models serve as a resource for public-private partnerships and for academic drug discovery efforts. These PDMs are clinically-annotated with molecular information and made available in the Patient-Derived Model Repository. Data related to the specific subjects in this Collection can be found at: